Lupin Limited (BOM:500257)
1,946.30
+94.70 (5.11%)
At close: Aug 7, 2025
Accolade Revenue
Lupin had revenue of 62.68B INR in the quarter ending June 30, 2025, with 11.93% growth. This brings the company's revenue in the last twelve months to 233.76B, up 12.40% year-over-year. In the fiscal year ending March 31, 2025, Lupin had annual revenue of 227.08B with 13.48% growth.
Revenue (ttm)
233.76B
Revenue Growth
+12.40%
P/S Ratio
3.75
Revenue / Employee
9.74M
Employees
24,006
Market Cap
875.47B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 227.08B | 26.97B | 13.48% |
Mar 31, 2024 | 200.11B | 33.69B | 20.25% |
Mar 31, 2023 | 166.42B | 2.36B | 1.44% |
Mar 31, 2022 | 164.05B | 12.43B | 8.19% |
Mar 31, 2021 | 151.63B | -2.12B | -1.38% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Reliance Industries | 9,765.41B |
HDFC Bank | 2,736.06B |
Bharti Airtel | 1,839.41B |
Tata Consultancy Services | 2,561.48B |
ICICI Bank | 2,054.85B |
State Bank of India | 3,429.39B |
Infosys | 1,672.76B |
Hindustan Unilever | 639.28B |
Lupin News
- 24 days ago - Lupin’s Pithampur Unit-3 gets 3 observations from US FDA after inspection - Business Upturn
- 25 days ago - Lupin launches generic Lotemax ophthalmic suspension in the U.S. market - Business Upturn
- 5 weeks ago - Lupin launches Ipratropium Bromide Nasal Solution (Nasal Spray) in the US market - Business Upturn
- 5 weeks ago - Lupin gets USFDA nod for Loteprednol Etabonate Ophthalmic Gel; Eligible for 180-day generic exclusivity - Business Upturn
- 5 weeks ago - Lupin carves out LupinLife into separate consumer healthcare subsidiary to focus on OTC consumer wellness market - Business Upturn
- 7 weeks ago - Lupin shares in focus as company signs respiratory drug deal in China with Sino Universal - Business Upturn
- 2 months ago - Lupin gets U.S. FDA tentative approval for Generic Oxcarbazepine ER Tablets - Business Upturn
- 2 months ago - Lupin to present Phase 1 data on LNP7457 cancer drug at ASCO 2025 - Business Upturn